Charles M. Baum M.D., Ph.D.
Net Worth

Last updated:

What is Charles M. Baum M.D., Ph.D. net worth?

The estimated net worth of Dr. Charles M. Baum M.D., Ph.D. is at least $60,965,616 as of 4 Jan 2023. He has earned $47,405,616 from insider trading and has received compensation worth at least $13,560,000 in Mirati Therapeutics, Inc..

What is the salary of Charles M. Baum M.D., Ph.D.?

Dr. Charles M. Baum M.D., Ph.D. salary is $1,130,000 per year as Founder, Pres, Head of R&D and Director in Mirati Therapeutics, Inc..

How old is Charles M. Baum M.D., Ph.D.?

Dr. Charles M. Baum M.D., Ph.D. is 67 years old, born in 1958.

What stocks does Charles M. Baum M.D., Ph.D. currently own?

As insider, Dr. Charles M. Baum M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Mirati Therapeutics, Inc. (MRTX) Founder, Pres, Head of R&D and Director 168,777 $0 $0

What does Mirati Therapeutics, Inc. do?

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

MRTX logo
MRTX
Mirati Therapeutics, Inc.

Charles M. Baum M.D., Ph.D. insider trading

Mirati Therapeutics, Inc.

Dr. Charles M. Baum M.D., Ph.D. has made 15 insider trades between 2013-2023, according to the Form 4 filled with the SEC. Most recently he sold 3,648 units of MRTX stock worth $169,997 on 4 Jan 2023.

The largest trade he's ever made was exercising 103,620 units of MRTX stock on 23 Feb 2018. As of 4 Jan 2023 he still owns at least 168,777 units of MRTX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 3,648 $46.6 $169,997
Sale
Common Stock 9,092 $40.42 $367,471
Option
Employee Stock Option (Right to Buy) 69,256 $17.41 $1,205,747
Sale
Common Stock 69,256 $100 $6,925,600
Option
Common Stock 69,256 $17.41 $1,205,747
Sale
Common Stock 2,517 $120.48 $303,253
Option
Common Stock 3,703 $27 $99,981
Option
Employee Stock Option (Right to Buy) 3,703 $27 $99,981
Sale
Common Stock 4,045 $147.73 $597,568
Sale
Common Stock 69 $149.09 $10,287
Option
Employee Stock Option (Right to Buy) 47,204 $8.49 $400,762
Option
Common Stock 47,204 $8.49 $400,762
Sale
Common Stock 47,204 $134.54 $6,350,968
Option
Employee Stock Option (Right to Buy) 40,000 $8.49 $339,600
Sale
Common Stock 40,000 $165.44 $6,617,760
Option
Common Stock 40,000 $8.49 $339,600
Option
Employee Stock Option (Right to Buy) 2,292 N/A N/A
Option
Common Stock 2,292 $5.4 $12,377
Option
Employee Stock Option (Right to Buy) 3,245 $27 $87,615
Option
Common Stock 3,245 N/A N/A
Sale
Common Stock 4,511 N/A N/A
Sale
Common Stock 40,000 $236.47 $9,458,880
Option
Common Stock 40,000 $8.49 $339,600
Option
Employee Stock Option (Right to Buy) 40,000 $8.49 $339,600
Option
Employee Stock Option (Right to Buy) 557 $5.4 $3,008
Option
Common Stock 557 $5.4 $3,008
Sale
Common Stock 40,000 $90.55 $3,621,800
Option
Employee Stock Option (Right to Buy) 40,000 $8.49 $339,600
Option
Common Stock 40,000 $8.49 $339,600
Option
Employee Stock Option (Right to Buy) 2,291 $5.4 $12,371
Option
Common Stock 2,291 $5.4 $12,371
Option
Common Stock 2,291 $5.4 $12,371
Option
Employee Stock Option (Right to Buy) 2,291 $5.4 $12,371
Option
Employee Stock Option (Right to Buy) 4,687 $15.2 $71,219
Option
Common Stock 4,687 $15.2 $71,219
Option
Common Stock 318 $15.2 $4,832
Option
Employee Stock Option (Right to Buy) 318 $15.2 $4,832
Option
Common Stock 52,368 $12.96 $678,846
Option
Stock Option (Right to buy) 52,368 $12.96 $678,846
Sale
Common Stock 51,810 $87.68 $4,542,804
Sale
Common Stock 51,810 $76.95 $3,986,728
Option
Common Stock 51,810 $8.5 $440,385
Option
Common Stock 103,620 $8.5 $880,770
Option
Stock Option (Right to Buy) 3,623 $17.3 $62,678
Option
Common Stock 3,623 $17.3 $62,678
Option
Common Stock 11,486 $17.41 $199,971
Option
Common Stock 22,972 $17.41 $399,943
Sale
Common Stock 51,810 $57.71 $2,990,162
Option
Common Stock 103,620 $8.5 $880,770
Option
Common Stock 51,810 $8.5 $440,385
Option
Common Stock 51,810 $8.5 $440,385
Sale
Common Stock 51,810 $28.23 $1,462,337
Option
Common Stock 103,620 $8.5 $880,770
Purchase
Common Stock 20,000 $7.05 $141,080
Option
Stock Option (Right to Buy) 11,778 $8.49 $99,995
Option
Common Stock 11,778 $8.49 $99,995
Option
Common Stock 11,778 $8.49 $99,995
Option
Stock Option (Right to Buy) 11,778 $8.49 $99,995
Purchase
Common Stock 5,000 N/A N/A

Mirati Therapeutics key executives

Mirati Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Charles M. Baum M.D., Ph.D. (67) Founder, Pres, Head of R&D and Director
  • Dr. James G. Christensen Ph.D. (57) Chief Scientific Officer
  • Mr. Benjamin J. Hickey M.B.A. (50) Chief Commercial Officer